Drug intelligence / Profile preview

CDD-2105 (Hong Kong Baptist University)

Development stage: Unknown
Lead developer: Hong Kong Baptist University
Administration: Oral

Overview

CDD-2105 is a Chinese herbal medicine formula developed by Hong Kong Baptist University for the treatment of constipation-predominant irritable bowel syndrome (IBS-C). It is administered as oral granules and is designed to alleviate symptoms including constipation and abdominal pain. The formula is currently undergoing evaluation in a double-blind, placebo-controlled, randomized pilot clinical trial to determine its efficacy and safety profile in adult patients.

Beyond the preview

Go deeper on CDD-2105 (Hong Kong Baptist University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDD-2105 (Hong Kong Baptist University).

Explore the full profile